Iloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management
AbstractIloperidone is a new atypical antipsychotic drug approved by FDA for the treatment of schizophrenia. In this article, we searched the published randomized controlled trials (RCT) and other literature to review the efficacy and safety of iloperidone using the following database (Science Direct, PubMed) and illustrate its role in the management of schizophrenia. Iloperidone showed efficacy by causing significant improvements in psychiatric scales such as Positive and Negative Syndrome scale (PANSS) and clinical global impressions (CGI). Iloperidone was associated with a number of common side effects such as metabolic and cardiovascular side effects. This review illustrated that iloperidone was well tolerated with significant improvements in disease severity and symptom intensity control in patients suffering with schizophrenia, however, iloperidone was associated with a significantly higher risk of metabolic and cardiovascular side effects with minimal extrapyramidal side effects. These findings would guide psychiatrists and pharmacists in their clinical role for supporting the care of psychiatric patients.
CitationReyad, AA., Mishriky, R. (2018) 'Iloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management', International Journal of Current Medical and Pharmaceutical Research,
PublisherVillupuram : journalcmpr
JournalInternational Journal of Current Medical and Pharmaceutical Research
The following licence applies to the copyright and re-use of this item:
- Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/